Third Dose Of Pfizer-BioNTech's COVID-19 Vaccine Boosts Protection Against Delta Variant, New Data Reveals
A third dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine can "strongly" boost protection against the delta variant beyond the protection afforded by the standard two doses.
Pfizer's new data suggest that antibody levels against the delta variant in people ages 18 to 55 who receive a third dose of vaccine are greater than five-fold than following a second dose.
Among people ages 65 to 85, the data exhibited that antibody levels against the delta variant after receiving the third dose of vaccine are greater than 11-fold than following a second dose.
There's an "estimated potential for up to a 100-fold increase in delta neutralization post-dose three compared to pre-dose three," researchers wrote in the Pfizer data slides.
The data have not yet been peer-reviewed or published and show that antibody levels are much higher after the third dose than a second dose against the original coronavirus strain and the beta variant, first identified in South Africa.
Pfizer posted Q2 results better than expected on Wednesday morning and forecasted billion from COVID-19 vaccine sales in FY2021.
Separately, the World Health Organization said it is not in favor of booster shots due to a lack of data.
Price Action: PFE shares are up 3.53% at $43.59, and BNTX stock is +7.10% at $303.98 during the market session on the last check Wednesday.
Photo by Spencer Davis from Pixabay
See more from Benzinga
WHO Is Currently Not In Favor Of COVID Booster Shots Citing Lack Of Data: CNBC
Pfizer Q2 Results Beat Wall Street Expectations; Expects B From COVID-19 Vax Sales In 2021
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
